Gonasi Kit (Human Chorionic Gonadotropin)

Gonasi Kit is employed in several reproductive‑medicine contexts where stimulation of the gonads is required.

• Induction of ovulation in women with anovulatory infertility.
• Luteal phase support following controlled ovarian stimulation in assisted reproductive technology (ART) cycles.
• Treatment of male hypogonadism to stimulate testosterone production.
• Management of cryptorchidism in prepubertal boys to promote testicular descent.
• Adjunct therapy in certain cases of delayed puberty.

Adverse reactions to Gonasi Kit vary in frequency and severity; they are reported in clinical studies and post‑marketing surveillance.

Common

• Injection site pain, redness or swelling.
• Headache or mild dizziness.
• Nausea or abdominal discomfort.
• Breast tenderness or swelling.
• Fluid retention leading to mild edema.

Serious

• Ovarian hyperstimulation syndrome (OHSS) presenting with rapid weight gain, abdominal distension, or shortness of breath.
• Allergic reactions such as urticaria, rash, or anaphylaxis.
• Thromboembolic events including deep vein thrombosis.
• Ectopic pregnancy risk when ovulation induction fails.

Before prescribing Gonasi Kit, clinicians should evaluate patient history and consider specific safety considerations.

• Confirm pregnancy status; hCG is contraindicated in established pregnancy except for specific ART protocols.
• Assess for ovarian cysts, polycystic ovary syndrome, or prior OHSS episodes.
• Review cardiovascular risk factors, as hCG can increase fluid retention and thrombotic risk.
• Evaluate for known hypersensitivity to hCG or any component of the formulation.
• Use caution in patients with thyroid disorders, because hCG can stimulate thyroid hormone production.
• Monitor serum estradiol and hCG levels during treatment to adjust therapy as needed.

Gonasi Kit may interact with other medications or substances that affect hormonal balance, coagulation, or immune response.

Avoid

• Concurrent use of estrogen‑containing contraceptives or hormone therapy that may exacerbate ovarian hyperstimulation.
• Anticoagulant therapy (e.g., warfarin, direct oral anticoagulants) without close monitoring due to increased thrombotic risk.

Use with caution

• Thyroid hormone replacement or antithyroid drugs, as hCG can influence thyroid function tests.
• Corticosteroids, which may mask allergic reactions.
• Medications that alter renal function, potentially affecting hCG clearance.